down arrow

Stella Pharma Corp.

  • Market Cap: Small Cap
  • Industry: Pharmaceuticals & Biotechnology
  • ISIN: JP3399680002
JPY
436.00
12 (2.83%)

Sep 24

TKS

 View all stocks in this country
  • Price Points
  • Score
  • Mojo Parameters
  • Total Return
  • News and Corporate Actions
  • Key factors
  • Shareholding
  • Financials
  • CompanyCV
stock-recommendationScore
Click here to find our call on this stock
Strong Sell
Sell
Hold
Buy
Strong Buy

Comparison

Company
Score
Quality
Valuation
Financial
Technical
Cyfuse Biomedical KK
Peptidream, Inc.
Oncolys BioPharma, Inc.
OncoTherapy Science, Inc.
GNI Group Ltd.
Carna Biosciences, Inc.
MEDINET Co., Ltd.
Chiome Bioscience, Inc.
StemCell Institute
SUSMED, Inc.
Stella Pharma Corp.

Why is Stella Pharma Corp. ?

1
Company's ability to service its debt is weak with a poor EBIT to Interest (avg) ratio of -188.60
  • Company's ability to service its debt is weak with a poor EBIT to Interest (avg) ratio of -188.60
2
Poor long term growth as Operating profit has grown by an annual rate -351.37% of over the last 5 years
3
The company has declared negative results for the last 3 consecutive quarters
  • NET SALES(HY) At JPY 154 MM has Grown at -80.74%
  • NET PROFIT(HY) At JPY -493.68 MM has Grown at -748.32%
  • INVENTORY TURNOVER RATIO(HY) Lowest at 0.04 times
4
Risky -
  • The stock is trading risky as compared to its average historical valuations
  • Over the past year, while the stock has generated a return of 22.13%, its profits have risen by 58.2%
5
Underperformed the market in the last 1 year
  • The stock has generated a return of 22.13% in the last 1 year, much lower than market (Japan Nikkei 225) returns of 43.58%
stock-recommendationReal-Time Research Report

Verdict Report

How much should you sell?

  1. All quantity irrespective of whether you are making profits or losses

(If sector exposure > 30%, please use optimiser tool to see which are the best stocks to hold in Pharmaceuticals & Biotechnology)

When to re-enter? - We will constantly monitor the company and review our call based on new data

Is Stella Pharma Corp. for you?

High Risk, Low Return

Absolute
Risk Adjusted
Volatility
Stella Pharma Corp.
22.13%
0.20
101.60%
Japan Nikkei 225
43.58%
1.48
29.43%
stock-recommendationQuality
stock-summaryManagement Risk
stock-summaryGrowth
stock-summaryCapital Structure
stock-recommendation
Quality grade scale :

Below Average, Average, Good, Excellent

Quality key factors

Factor
Value
Sales Growth (5y)
64.44%
EBIT Growth (5y)
-351.37%
EBIT to Interest (avg)
-209.71
Debt to EBITDA (avg)
Negative Net Debt
Net Debt to Equity (avg)
-0.76
Sales to Capital Employed (avg)
0.15
Tax Ratio
0.37%
Dividend Payout Ratio
0
Pledged Shares
0
Institutional Holding
0
ROCE (avg)
0
ROE (avg)
0
stock-recommendationValuation

Valuation Scorecard stock-summary

stock-recommendation
Valuation grade scale :

Very Risky, Risky, Very Expensive, Expensive, Fair, Attractive, Very Attractive

Valuation Key Factors stock-summary

Factor
Value
P/E Ratio
NA (Loss Making)
Industry P/E
Price to Book Value
4.32
EV to EBIT
-42.70
EV to EBITDA
-49.49
EV to Capital Employed
12.30
EV to Sales
10.04
PEG Ratio
NA
Dividend Yield
NA
ROCE (Latest)
-28.80%
ROE (Latest)
-10.36%
stock-recommendationTechnicals

Technical key factors

Indicator
Weekly
Monthly
MACD
Mildly Bullish
Bearish
RSI
Bullish
No Signal
Bollinger Bands
Bullish
Bullish
Moving Averages
Mildly Bearish (Daily)
KST
Mildly Bullish
Bullish
Dow Theory
Mildly Bullish
Mildly Bullish
OBV
No Trend
Mildly Bullish
stock-recommendation Technical Indicator Scale: Bearish, Mildly Bearish, Sideways, Mildly Bullish, Bullish  Turned 
Technical Movement
Analyse All Technical Factors stock-recommendation
stock-recommendationFinancial Trend

Financial Trend Scorecard stock-summary

stock-recommendation
Financial Trend scale:

Very Negative, Negative, Flat, Positive, Very Positive, Outstanding

3What is working for the Company
RAW MATERIAL COST(Y)

Fallen by 1.01% (YoY

CASH AND EQV(HY)

Highest at JPY 6,624.01 MM

NET SALES(Q)

At JPY 92.4 MM has Grown at 14.29%

-30What is not working for the Company
NET SALES(HY)

At JPY 154 MM has Grown at -80.74%

NET PROFIT(HY)

At JPY -493.68 MM has Grown at -748.32%

INVENTORY TURNOVER RATIO(HY)

Lowest at 0.04 times

DEBTORS TURNOVER RATIO(HY)

Lowest at 0.78 times

INTEREST(Q)

Highest at JPY 3.82 MM

OPERATING PROFIT(Q)

Lowest at JPY -238.05 MM

Here's what is working for Stella Pharma Corp.

Net Sales
At JPY 92.4 MM has Grown at 14.29%
over average net sales of the previous four periods of JPY 80.85 MM
MOJO Watch
Near term sales trend is positive

Net Sales (JPY MM)

Cash and Eqv
Highest at JPY 6,624.01 MM
in the last six Semi-Annual periods
MOJO Watch
Short Term liquidity is improving

Cash and Cash Equivalents

Raw Material Cost
Fallen by 1.01% (YoY)
MOJO Watch
The company's ability to pass on the cost of raw materials to customers has improved; this may lead to a rise in profit margin

Raw Material Cost as a percentage of Sales

Here's what is not working for Stella Pharma Corp.

Net Profit
At JPY -493.68 MM has Grown at -748.32%
Year on Year (YoY)
MOJO Watch
Near term Net Profit trend is very negative

Net Profit (JPY MM)

Interest
At JPY 3.82 MM has Grown at 27.96%
period on period (QoQ)
MOJO Watch
Rising interest cost signifies increased borrowings

Interest Paid (JPY MM)

Interest
Highest at JPY 3.82 MM
in the last five periods and Increased by 27.96% (QoQ)
MOJO Watch
Rising interest cost signifies increased borrowings

Interest Paid (JPY MM)

Operating Profit
Lowest at JPY -238.05 MM
in the last five periods
MOJO Watch
Near term Operating Profit trend is negative

Operating Profit (JPY MM)

Inventory Turnover Ratio
Lowest at 0.04 times
in the last five Semi-Annual periods
MOJO Watch
Company's pace of selling inventory has slowed

Inventory Turnover Ratio

Debtors Turnover Ratio
Lowest at 0.78 times
in the last five Semi-Annual periods
MOJO Watch
Company's pace of selling Debtors has slowed

Debtors Turnover Ratio

Footer loading